Education
About Us
Working with TipRanks
Follow Us
Personalis Inc (PSNL)
NASDAQ:PSNL
PSNL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.83 - $7.79
Previous CloseN/A
Volume738.16K
Average Volume (3M)1.03M
Market Cap
$432.74M
Enterprise Value$450.71M
Total Cash (Recent Filing)$173.23M
Total Debt (Recent Filing)$42.44M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 05, 2025EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding88,677,060
10 Day Avg. Volume912,098
30 Day Avg. Volume1,025,489
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue5.61
Enterprise Value/Gross Profit17.84
Enterprise Value/Ebitda-5.58
Forecast
1Y Price Target
$7.58Price Target Upside58.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical Test GrowthPSNL drove strong +59% q/q growth of its clinical tests with its partner Tempus and reaffirmed its goal to obtain two Medicare coverage determinations by YE'25.
MRD StrategyNeXT Personal MRD continues to resonate with docs, is building traction.
Pharma ContractsPSNL has had recent wins with pharma companies, as it announced that it signed two MRD contracts with biopharma companies expected to contribute $5M apiece this year.
Bears Say
Lowered Revenue GuidancePSNL's 2Q25 revenue missed consensus and management lowered their 2025 revenue guidance.
Pharma Services SoftnessPSNL specifically called out softness in the translational side of its pharma services business, including from Moderna.
Revenue MissThe company reported total revenues of $17.2M, below the consensus estimate of $20.1M.
Personalis News
PSNL FAQ
What was Personalis Inc’s price range in the past 12 months?
Personalis Inc lowest stock price was $2.83 and its highest was $7.79 in the past 12 months.
What is Personalis Inc’s market cap?
Personalis Inc’s market cap is $432.74M.
When is Personalis Inc’s upcoming earnings report date?
Personalis Inc’s upcoming earnings report date is Nov 05, 2025 which is in 68 days.
How were Personalis Inc’s earnings last quarter?
Personalis Inc released its earnings results on Aug 05, 2025. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.24 by $0.01.
Is Personalis Inc overvalued?
According to Wall Street analysts Personalis Inc’s price is currently Undervalued.
Does Personalis Inc pay dividends?
Personalis Inc does not currently pay dividends.
What is Personalis Inc’s EPS estimate?
Personalis Inc’s EPS estimate is -0.28.
How many shares outstanding does Personalis Inc have?
Personalis Inc has 88,677,060 shares outstanding.
What happened to Personalis Inc’s price movement after its last earnings report?
Personalis Inc reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.24. Following the earnings report the stock price went down -21.986%.
Which hedge fund is a major shareholder of Personalis Inc?
Currently, no hedge funds are holding shares in PSNL
Personalis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.58 (58.58% Upside)
$7.58 (58.58% Upside)
Blogger Sentiment
Bullish
PSNL Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 238.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.01%
12-Months-Change
Fundamentals
Return on Equity
-60.26%
Trailing 12-Months
Asset Growth
39.45%
Trailing 12-Months
Company Description
Personalis Inc
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
PSNL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed view with significant achievements in clinical adoption and potential growth opportunities in MRD, yet faced challenges with revenue decline, biopharma project delays, and gross margin pressures. The company remains confident about future reimbursement outcomes and growth potential.View all PSNL earnings summariesPSNL Stock 12 Month Forecast
Average Price Target
$7.58
▲(58.58% Upside)
Technical Analysis
Ownership Overview
21.76% Insiders
3.37% Mutual Funds
46.13% Other Institutional Investors
12.90% Public Companies and
Individual Investors